Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
BofA Securities raised its price target on DigitalOcean (DOCN) to $72 from $60 and maintained a Buy rating, pointing to accelerating interest in agentic AI frameworks such as Clawdbot and the company's positioning to host always-on inferencing workloads. The move follows strong recent price performance and positive operational signals, including qu…
BofA Securities reduced its 12-month price target for CVS Health to $95 from $100 but kept a Buy rating, after the Centers for Medicare & Medicaid Services put forward changes to Medicare Advantage payment methodology that could lower industry payments. The CMS proposals include a lower net all-in rate and a new CMS-HCC risk-adjustment model that w…
China’s Defence Minister Dong Jun told his Russian counterpart Andrei Belousov in a video call that Beijing wants to strengthen strategic coordination, implement top-level consensus, expand cooperation substance and improve exchange mechanisms. Dong said China is prepared to work with Russia to boost their joint capacity to respond to unspecified r…
North Korea fired several ballistic missiles toward waters off its east coast on Tuesday, South Korean and Japanese authorities reported. The projectiles, assessed as likely short-range, were launched from near Pyongyang in the mid-afternoon and travelled roughly 350 km. The episode occurred as senior U.S. and South Korean officials meet to discuss…
BofA Securities reduced its target on Teladoc Health to $7 from $7.50 while keeping a Neutral rating, citing continued uncertainty in the company’s BetterHelp and Chronic Care segments. The firm lowered its valuation multiple to 4.1x calendar year 2026 EBITDA and noted flat sequential BetterHelp user growth alongside weaker year-over-year trends. T…
Jefferies has initiated coverage of two major Dutch lenders, assigning ABN Amro a "hold" rating with a €15 price target and ING a "buy" rating with a €18.50 price target. The brokerage said ABN Amro’s current share price appears close to fair value given its capital and earnings outlook, while ING’s stronger earnings momentum, broader business mix …
One year after the executive order creating the Golden Dome missile-defense initiative, the program has spent little of the $25 billion appropriated and remains stalled while officials and industry stakeholders debate classified elements of its space-based architecture. Small prototype contracts have been awarded, but major procurement and broad fu…
President Donald Trump will visit Iowa as mounting pressure in the farm economy and postponed biofuel decisions create strains for farmers and renewable-fuel producers. The stop is aimed at shoring up support in a state that is the nation's largest producer of corn, hogs and ethanol, even as farmers report cash-flow stress, lower crop prices and un…
Starbucks has made inventory reliability a central priority for CEO Brian Niccol, yet persistent shortages of everyday items across thousands of U.S. coffeehouses reflect deeper operational and technological failings. Interviews with current and former corporate employees, review of internal media and photographs, and company statements show recurr…
Citi has opened coverage on six leading European pharmaceutical groups with a constructive sector view. The bank rates AstraZeneca, Novartis and Roche as Buy, while GSK, Sanofi and Novo Nordisk receive Neutral ratings. Citi points to an unusually deep late-stage pipeline and expects resilient earnings growth driven by new product launches that larg…
After roughly four years of subdued initial public offering activity, Canada’s primary equity market is showing signs of revival for 2026. Market participants say high interest rates and inflation, regulatory friction, and other headwinds kept many firms out of the public markets, but recent equity market strength and a sizable October deal have en…
Allstate is trading like underwriting is still fully at the mercy of the cycle. But the profitability profile implied by a 30% ROE and a single-digit P/E suggests a structurally improved earnings engine. With the stock sitting below key moving averages and momentum still bearish, this is a mid-term long idea that looks like it’s offering entry rath…
Shares of major US health insurers fell sharply in premarket trading after the Centers for Medicare and Medicaid Services proposed a 0.09% increase to Medicare Advantage payment rates for 2027. The modest update, which CMS said produces just over $700 million in additional payments, came well below analyst expectations and has raised concerns about…
Pfizer is trading around $25.88 with improving momentum and a 6.65% dividend yield. Even as the market debates big-picture healthcare policy shifts, PFE’s valuation looks compressed versus its cash generation profile and the stock is building a base just under the 52-week high. This trade idea targets a measured breakout with defined risk, leaning …
Futures tied to the S&P 500 and Nasdaq moved up on Jan. 27 as market participants prepared for a heavy roster of corporate earnings reports. Dow futures lagged after a sharp selloff in UnitedHealth linked to a government proposal to adjust Medicare insurer payment rates. The Federal Reserve begins a two-day policy meeting the same day, and a st…
Kepler Cheuvreux moved Atrium Ljungberg from Buy to Hold and left its price target unchanged at SEK 36, citing reduced upside after a 6% share rise since the October upgrade and a subdued funds from operations growth outlook. The research house forecasts negative FFO CAGR for 2025-2027, expects a sequential dip in rental income in Q4, and anticipat…
UnitedHealth said it expects adjusted 2026 earnings per share just above analysts' consensus, signaling initial benefits from recent medical cost-control measures. The company nevertheless flagged ongoing challenges in Medicaid and government-backed plans and noted that a proposed minimal Medicare Advantage rate increase weighed on insurer stocks.
Jefferies raised its price target for Caterpillar to $750 from $700 while retaining a Buy rating, pointing to a favorable 2026 outlook for the Construction Industries segment and possible upside in Resource Industries. The new target implies a 25x multiple on Jefferies' 2026 EBITDA estimate. The upgrade comes ahead of Caterpillar's January 29 earni…
Morgan Stanley trimmed its rating on Clearwater Analytics Holdings (CWAN) from Overweight to Equalweight and reduced its price target to $24.55 from $27.00 following the close of the company's go-shop period. The revised target reflects the agreed acquisition price of $24.55 per share, and follows a go-shop during which Clearwater solicited interes…
TD Cowen has initiated coverage of Zimmer Biomet (NYSE: ZBH) with a Buy rating and a $109 price target, implying about 25% upside from the current share price of $87.32. The firm points to a stronger growth and profitability outlook, underpinned by a 71.6% gross profit margin and 5.5% revenue growth over the past 12 months, while noting prior execu…
TD Cowen initiated coverage of Beta Bionics (NASDAQ:BBNX) with a Hold rating and a $17.00 price target, noting solid early commercial traction for the iLet system but expressing concerns that projected revenue gains may not justify an outsized valuation. The firm highlighted strong recent top-line growth alongside signs of a potential slowdown in n…
TD Cowen began coverage of Stryker Corporation (NYSE: SYK) with a Hold rating and a $387 price target shortly before the company's upcoming earnings report. The firm praised Stryker's long run of organic growth and renewed focus on margins, while noting valuation metrics that present both potential upside and premium multiples. Recent corporate mov…
Dr Martens reported a decline in quarterly revenue and signalled broadly flat annual revenue growth after rolling back promotions, a move that depressed sales in Europe and the Asia-Pacific region. The company said U.S. customers were more accepting of full pricing, driving modest growth in the Americas, while management kept a forecast for signifi…
Spotify has pulled back sharply from its 52-week highs and is now sitting near short-term moving averages with an oversold RSI around 35. The tape still shows bearish momentum, but the dip is starting to look more like exhaustion than the start of a fresh breakdown. This trade idea is a defined-risk long that leans on mean reversion back toward the…
J.P. Morgan has put Legrand on a positive catalyst watch ahead of the group's fourth-quarter results due Feb. 12, reiterating an overweight rating and a €165 price target. The bank highlights upside versus consensus for the quarter, the company's exposure to robust data-center demand, a valuation discount relative to peers, and elevated short inter…
